Reportlinker Adds The Turkish Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

Jan 19, 2010, 07:55 ET from Reportlinker

NEW YORK, Jan. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Turkish Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

http://www.reportlinker.com/p0172205/The-Turkish-Pharmaceutical-Market-Outlook-to-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities.html

Turkey, a 'pharmerging' market, has evolved to this status after a series of economic and healthcare reforms. The country was at the verge of financial collapse until 2001 with inflation running in near three digits. However, the economic reforms implemented by the country have turned it into a dynamic economy. The country's pharmaceutical industry has been a frontrunner in these reforms. Turkey has a growing pharmaceutical sector with around 300 pharmaceutical companies selling up to 1.3bn units of products every year. Factors that have fuelled the growth of the pharmaceutical industry in the country include economic growth, high healthcare expenditures, a young workforce and a host of companies delivering drugs to the populace.

The reforms taken up by the country made the healthcare system more efficient, improving access for the population, besides bringing the system in sync with the standards of other EU nations. At the same time, the country's growing economic consistency brought in foreign investment in the sector and bolstered consumer spending on pharmaceuticals. The healthcare reforms taken up by the country included implementation of a patent legislation in 1995, creation of a generics registration law in 1996 and establishment of a reference pricing system in 2004. However, the industry continues to have some problems still, such as a protracted product registration system and a reimbursement list that is deemed incomplete and biased.

Key features of this report

  • Epidemiological analysis of the major diseases and forecast prevalence of the common diseases over the period 2008-14 .
  • Macroeconomic analysis of the country with a special focus on the healthcare sector reforms and its impact analysis.
  • An overview of the IPR climate, the recent amendments and current state of pharmaceutical innovation.
  • Detailed analysis of the leading therapeutic categories and classes including forecast sales over the period 2008-2014 and a review of the leading brands in each.

Scope of this report

  • Develop an understanding of the Turkish healthcare system and the issues facing it.
  • Understand the IP laws in Turkey and how they affect the pharmaceutical R&D pipeline.
  • Understand how the companies are altering their strategies and adopting new business models to sustain profitable growth in the new political and economic climate.
  • Gain up-to-date competitive intelligence and understand the major issues affecting the pharmaceutical major.
  • Compare the franchises of top pharmaceutical players across major indications, and understand how market share of leading companies will change over the next six years.

Key Market Issues

  • Targeting niche therapeutic segments and overseas expansion

Although Turkish companies have prospered in recent years, intense generic competition and regulatory hurdles have forced many local manufacturers to look for niche products and overseas markets to expand and drive future revenue growth.

  • Few local manufacturers with FDA approved sites

Even though, Turkey has a large number of local manufacturers, only few of them have FDA approved production sites. For example, Mustafa Nevzat, one of the few FDA approved companies for finished products, is developing a production facility for oncology drugs which could export drugs to the US in the near future.

  • A lengthy reimbursement review process

In Turkey, the average time a medicine spends in reimbursement review is over 225 days, which is much above the optimum time of 90 days. Besides, usage of generics is encouraged and so specialized therapeutics that have no generic equivalents seem to suffer.

Key findings from this report

  • Turkey's Ministry of Health (MoH) was one of the first state run bodies in the world to focus on disease prevention and not just treatment. MoH still remains the only body in the country that provides preventative healthcare services, besides being a key provider of primary and secondary care.
  • Over the recent past, Turkey has been improving its healthcare services by importing large quantities of modern machinery and equipment to improve the healthcare services in hospitals. In 2006 the MoH initiated a project to build medical centers in three major cities. The government has also been encouraging multinational companies to invest in the country's healthcare industry.

Key questions answered

  • How is the regulatory set up of the Turkish pharmaceutical market?
  • How does the Turkish pharmaceutical market compare with other emerging pharmaceutical markets?
  • What will be the major growth drivers in the Turkish pharmaceutical market over the period 2008-14?
  • Which companies were leading in the Turkish pharmaceutical market in 2008?
  • What are the key relative strengths of the leading companies?

Table of Contents

The Turkish Pharmaceutical Market Outlook to 2014

Executive Summary 10

Turkey – an overview 10

Turkey – healthcare system and regulation 11

Turkish pharmaceutical market 12

Competitive landscape 13

Scope and methodology 15

Scope 15

Methodology 15

Chapter 1 Turkey – an overview 18

Summary 18

Introduction 19

The government 19

The economy 20

Key economic parameters 21

Population profile and demographic trends 22

Disease burden 22

Forecast epidemiology 24

Chapter 2 Turkey – healthcare system and regulation 28

Summary 28

Introduction 29

Key recent events 29

Prescription regulation suspended 29

Furthering the healthcare reforms agenda 30

A snapshot of the healthcare reforms in the country 30

Turkey healthcare system 31

Organization/administration 31

Financing healthcare 34

Health insurance 34

Reimbursement 36

Healthcare expenditure 37

Drug regulation 37

Intellectual property rights 37

Securing a marketing authorization 38

Drug pricing 41

Pharmaceutical distribution channels 41

Chapter 3 Turkish pharmaceutical market 44

Summary 44

Introduction 45

Key recent issues 45

The Turkish government's planned price reforms may adversely affect pharmaceutical growth 45

Key recent events 46

Zentiva acquired a majority stake in Eczacibasi's pharmaceutical and fine chemicals division 46

Daiichi Sankyo focuses on acquisition-driven growth in Turkey 46

Pharming and Aslan Group signed a licensing agreement for lactoferrin 46

Vical licenses melanoma drug Allovectin-7 to Eczacibasi 47

Therapy area analysis 47

Therapy area sales forecast 2008–14 55

Leading brands 56

Leading brands sales forecast 58

Generic pharmaceutical market in Turkey 58

Performance of generics across therapy areas 63

Leading generic products 65

Chapter 4 Competitive landscape 68

Summary 68

Introduction 69

Competitive positioning of the leading players in the Turkish pharma market 70

Detailed analysis of major foreign pharmaceutical players in Turkey 72

Novartis 72

Overview 72

Sales focus by leading drug class 72

Marketed product portfolio 74

Novartis' pipeline focus 77

Strategic growth analysis 78

Sanofi-Aventis 81

Overview 81

Sales focus by leading drug class 81

Marketed product portfolio 82

Sanofi-Aventis pipeline focus 84

Strategic growth analysis 85

Pfizer 87

Overview 87

Sales focus by leading drug class 87

Marketed product portfolio 89

Pfizer's pipeline focus 91

Strategic growth analysis 93

GSK 95

Overview 95

Sales focus by leading drug class 95

Marketed product portfolio 97

GSK's pipeline focus 99

Strategic growth analysis 100

Detailed analysis of key domestic pharmaceutical players in Turkey 102

Ibrahim 102

Overview 102

Sales focus by leading drug class 102

Marketed product portfolio 104

Ibrahim's pipeline focus 105

Strategic growth analysis 106

Bilim 107

Overview 107

Sales focus by leading drug class 107

Marketed product portfolio 109

Bilim's pipeline focus 110

Strategic growth analysis 110

Competitive positioning of leading generic players in Turkey 111

Chapter 5 Appendix 114

Anatomical therapeutic classification (ATC) 114

A: Alimentary tract and metabolism 114

B: Blood and blood-forming organs 114

C: Cardiovascular system 114

D: Dermatologicals 115

G: Genitourinary system and sex hormones 115

H: Systemic hormonal preparations 115

J: General anti-infectives systemic 115

K: Hospital solutions 115

L: Antineoplastic and immunomodulating agents 115

M: Musculoskeletal system 116

N: Nervous system 116

P: Parasitology 116

R: Respiratory system 116

S: Sensory organs 116

T: Diagnostic agents 116

V: Various 116

Forecast factors 117

Glossary 118

Index 119

List of Figures

Figure 1.1: Percentage change in deaths by disease category in Turkey, 2000–05 24

Figure 2.2: Organization of the Turkish healthcare system 33

Figure 3.3: Top 10 drug classes of the anti-infective therapy area ($m), 2008 49

Figure 3.4: Top 10 drug classes of the alimentary tract and metabolism therapy area ($m), 2008 50

Figure 3.5: Top 10 drug classes of the cardiovascular system therapy area ($m), 2008 51

Figure 3.6: Top 10 drug classes of the nervous system therapy area ($m), 2008 52

Figure 3.7: Top 10 drug classes of the respiratory system therapy area ($m), 2008 53

Figure 3.8: Growth analysis of therapy areas in Turkey, 2007–08 54

Figure 3.9: Comparative performance of generic and branded market segments in Turkey, 2007– 08 61

Figure 3.10: Comparative performance of generic and branded market segments in Turkey and 7MM, 2007–08 62

Figure 3.11: Growth analysis of therapy areas in the Turkish generic market Turkey, 2008 64

Figure 4.12: Top 10 companies positioning in Turkey based on prescription sales, 2008 71

Figure 4.13: Novartis' Turkish pharmaceutical market sales by therapy area, 2008 73

Figure 4.14: Sanofi-Aventis' Turkish pharmaceutical market sales by therapy area, 2008 82

Figure 4.15: Pfizer's Turkish pharmaceutical market sales by therapy area, 2008 88

Figure 4.16: GSK's Turkish pharmaceutical market sales by therapy area, 2008 96

Figure 4.17: Ibrahim's Turkish pharmaceutical market sales by therapy area, 2008 103

Figure 4.18: Bilim's Turkish pharmaceutical market sales by therapy area, 2008 108

Figure 4.19: Positioning of top 10 generic players in Turkey, 2008 112

List of Tables

Table 1.1: Key political parameters of Turkey 20

Table 1.2: Key economic parameters of Turkey 21

Table 1.3: Key demographic parameters of Turkey 22

Table 1.4: Forecast epidemiology of common risk factors in Turkey, 2008–14 25

Table 2.5: Comparison of key healthcare system parameters of Turkey with OECD average 33

Table 2.6: Biosimilar products registered in EU till June 2009 41

Table 3.7: Turkey pharmaceutical market by therapy area sales, 2008 48

Table 3.8: Turkish pharmaceutical market therapy area sales forecast ($m), 2008–14 55

Table 3.9: Turkish pharmaceutical market by leading brands, 2008 56

Table 3.10: Top 10 brands of the Turkish pharmaceutical market, sales forecast 2008–14 58

Table 3.11: Generic pharmaceutical market in Turkey, 2008 60

Table 3.12: Generic pharmaceutical sales across therapy areas, 2008 63

Table 3.13: Top 10 generic products in Turkey, 2008 65

Table 4.14: Leading companies in the Turkish pharmaceutical market based on prescription sales, 2008 70

Table 4.15: Novartis' leading brands in the Turkish pharmaceutical market, 2008 75

Table 4.16: Sanofi-Aventis' leading brands in the Turkish pharmaceutical market, 2008 83

Table 4.17: Pfizer's leading brands in the Turkish pharmaceutical market, 2008 89

Table 4.18: GSK's leading brands in the Turkish pharmaceutical market, 2008 97

Table 4.19: Ibrahim's leading brands in the Turkish pharmaceutical market, 2008 104

Table 4.20: Bilim's leading brands in the Turkish pharmaceutical market, 2008 109

Table 4.21: Leading generic players in the Turkish pharmaceutical market, 2008 113

To order this report:

Pharmaceutical Industry: The Turkish Pharmaceutical Market Outlook to 2014: Policy environment, market structure, competitive landscape, growth opportunities

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com